BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW)

CUSIP: 10778Y112

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Equity / *W EXP 02/26/202
Total 13F shares
1,174,328
Share change
+171,969
Total reported value
$6,106,000
Price per share
$5.20
Number of holders
9
Value change
+$893,730
Number of buys
6

Quarterly Holders Quick Answers

What is CUSIP 10778Y112?
CUSIP 10778Y112 identifies BCTXW - BriaCell Therapeutics Corp. - *W EXP 02/26/202 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW) as of Q1 2022

As of 31 Mar 2022, BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW) was held by 9 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,174,328 shares. The largest 9 holders included Murchinson Ltd., ARMISTICE CAPITAL, LLC, K.J. Harrison & Partners Inc, Redmond Asset Management, LLC, ZEKE CAPITAL ADVISORS, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Warberg Asset Management LLC, Warberg Asset Management LLC, and UBS Group AG. This page lists 9 institutional shareholders reporting positions in this security for the Q1 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.